BRIEF — Belite Bio Announces Multi — Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Oct 14 (Reuters) — Belite Bio, Inc: Belite Bio Announces Multi-market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1 Belite Bio - Submits Marketing Authorization Applications For Tinlarebant In Singapore, Uk, And Switzer